Congenital CMV Linked to Pediatric Hyperdiploid ALL Congenital CMV Linked to Pediatric Hyperdiploid ALL
Early congenital cytomegalovirus could be a modifiable risk factor for childhood hyperdiploid acute lymphoblastic leukemia but more research delineating a mechanism is warranted.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Single - Tube Multiparametric Flow Cytometry Predicts Treatment Response in Leukemia
Multiparametric flow cytometry has excellent prediction for survival among patients with B - cell acute lymphoblastic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 21, 2022 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news

Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
Rylaze dosing options provide sustained asparaginase activity throughout the entire course of treatment for adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma DUBLIN, Nov. 18, 2022 /PRNewswire/ -- Jazz... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 18, 2022 Category: Drugs & Pharmacology Source Type: news

Novel Co-Admin of CAR T Cells Achieves 99% Remission in Leukemia Novel Co-Admin of CAR T Cells Achieves 99% Remission in Leukemia
In the largest study to date of CAR T-cell therapy for relapsed and refractory childhood B-cell acute lymphoblastic leukemia, a novel approach led to undetectable disease in nearly all patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 8, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

St. Jude Children ’s Research Hospital has a new clinical trial for relapsed leukemia
A specific type of drug-resistant, relapsed pediatric cancer is the focus of a new clinical trial at St. Jude Children's Research Hospital. The phase I/II clinical trial called RAVEN aims to research a new treatment option for children with relapsed acute lymphoblastic leukemia (ALL) — a severe cancer of blood and bone marrow that attacks white blood cells. According to Dr. Seth Karol, the trial's principal investigator and St. Jude associate faculty member, RAVEN uses a combination of traditional… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 27, 2022 Category: Biotechnology Authors: Aishwarya Airy Source Type: news

Cesarean Section Tied to Higher Risk for Later Leukemia in Offspring
Findings strongest for elective cesarean section and acute lymphoblastic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2022 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Oncology, Pediatrics, Surgery, Journal, Source Type: news

CAR-T Therapy Effective in Youngest Kids With ALL
(MedPage Today) -- The use of tisagenlecleucel (Kymriah) in children younger than 3 years of age with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) was as effective, and safe, in a retrospective cohort study as it was previously... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 8, 2022 Category: Hematology Source Type: news

Leukemia Rates 2-3X Higher in Kids Born Near Fracking Leukemia Rates 2-3X Higher in Kids Born Near Fracking
The study compared proximity of homes to unconventional oil and gas development sites and risk of the most common form of childhood leukemia, acute lymphoblastic leukemia.WebMD Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Higher Tisagenlecleucel Doses May Improve Outcomes in Youth With B-ALL
TUESDAY, Aug. 9, 2022 -- For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel, the chimeric antigen receptor T (CAR T)-cell therapy targeting CD19, are associated with improved survival, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 9, 2022 Category: Pharmaceuticals Source Type: news

17-year-old is declared cured of cancer 10 years after undergoing revolutionary therapy
Emily Whitehead, 17, from Philipsburg, Pennsylvania, was five-years-old when she was diagnosed with acute lymphoblastic leukemia (ALL) in 2010. (Source: the Mail online | Health)
Source: the Mail online | Health - July 22, 2022 Category: Consumer Health News Source Type: news

CAR T-Cell Therapy Turns 10 and Finally Earns the Word'Cure'CAR T-Cell Therapy Turns 10 and Finally Earns the Word'Cure '
Emily Whitehead is the first of many children with refractory acute lymphoblastic leukemia to achieve complete remission and a"functional cure."Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 21, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
Recently,NBC News ’ Todaydid aprofile on one of the first pediatric patients in the world to receive a CAR-T cell therapy for the treatment of acute lymphoblastic leukemia (ALL). In April 2012, the patient was able to enroll in a pediatric phase I clinical trial to receive the CAR-T cell therapy,CTL019 or tisagenlecleucel.During the process, the patient ’s T-cells were separated from the bloodstream and genetically engineered to express a chimeric antigen receptor (CAR) — an artificial receptor that allows T-cells to recognize cancerous cells. Once returned to the body, the re-engineered cells enabled the patient’s...
Source: The Catalyst - May 25, 2022 Category: Pharmaceuticals Authors: Matthew Norawong Tags: Cancer Immunotherapy Source Type: news

Biomarker Predicts Nonresponse to CAR T in Pediatric ALL Biomarker Predicts Nonresponse to CAR T in Pediatric ALL
Alternative strategies could be offered to children and young adults with advanced acute lymphoblastic leukemia (ALL) identified as being unlikely to respond to the expensive therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 18, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

AACR: Resistance Mechanisms to CAR-T Cell Therapy ID'd in ALL
TUESDAY, April 12, 2022 -- For patients with acute lymphoblastic leukemia with resistance to C19 CAR T-cell therapy, resistance mechanisms that can be detected prior to treatment have been identified, according to a study presented at the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2022 Category: Pharmaceuticals Source Type: news